Trial Profile

Prospective randomized phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Sunitinib (Primary)
Indications Pancreatic cancer
Focus Therapeutic Use
Acronyms CESAR

Most Recent Events

04 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met according to results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
30 Nov 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
30 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com